(TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. 51 S1. FAQ – Utilisateurs de TMX Argent NOUVEAU. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. MONTREAL, Nov. - Q3 2022 North American Revenue Growth of 19%. Their THTX share price targets range from $36. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. 66% compared to the previous year's 69. - 2023 Q3 positive adjusted EBITDA to be. T. MONTREAL, Feb. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Website. FAQ – Émetteurs inscrits NOUVEAU. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The abstracts are now available at aacr. $30. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. Theratechnologies Inc. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. Follow. MONTREAL, Sept. Stockhouse. Northwest also announces an update on its. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. 00, suggesting a possible upside of. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. : Nasdaq Theratechnologies Inc. L. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. Theratechnologies Inc. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. 71. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. 54% and a negative trailing twelve-month return on equity of 1,116. During the last trading day the stock fluctuated 12. com. 28 $1. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. Theratechnologies’ R&D staff is bearing the brunt of. Their average twelve-month price target is $36. By continuing to use our service, you agree to our use of cookies. US Headquarters. It is the Company’s proprietary. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Stockhouse. 1300 (+9. Phone Number (514) 336-7800. 82 million. This news release constitutes a “designated news release” for the purposes of the Company’s. com uses cookies on this site. acts as investment manager. About Us | Theratechnologies Inc. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. ET. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. 22M. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. Stockhouse. There are 102 news items for this page. T. Cookies are used to offer you a better browsing experience and to analyze our traffic. Get the latest Sernova Corp (SVA) real. Further. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. - Q3 2022 Consolidated Revenue Growth of 17% to $20. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. 1-514-336-7800. 35 as of 10:41 a. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. Unveiling Silvercorp's golden potential at the Ying Mining District. . 00. 8. We currently market prescription products for people with. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. 17. 63. S. GUD | Complete Knight Therapeutics Inc. com uses cookies on this site. Theratechnologies inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. First Quarter Fiscal 2022 Financial Results. Stockhouse. Elif McDonald - Senior Director, Investor Relations. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. TO) on CEO. US Headquarters. Theratechnologies develops and commercializes innovative therapies. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. is a speaker and consultant of Theratechnologies. We also use them to. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. Find the latest Theratechnologies Inc. If you have HIV, it's important to know the difference. com uses cookies on this site. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. Stockhouse. One reason for that is that this tier does not include penny stocks. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. 2% per year. Q3 2023 consolidated revenue of $20. Cookies are used to offer you a better browsing experience and to analyze our traffic. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. THTX | Complete Theratechnologies Inc. MONTREAL, Aug. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We currently market prescription products for people with HIV in the United States. We also use them to share usage. com. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. 08 (+6. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. Theratechnologies Inc. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. We currently market prescription products for people with HIV in the United States. com. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Stockhouse. P. (Image via Theralase Technologies Inc. Theratechnologies Inc. Denis Boucher. Theratechnologies's earnings have been declining at an average annual rate of -35. Message Board Total Posts: 4. The reported ($0. Theratechnologies last announced its earnings data on September 26th, 2023. 5000 0. com. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. TH | July 20, 2023. com uses cookies on this site. Data presented at AMCP Nexus 2023. Montréal, Québec, Canada . com. Theratechnologies Inc. . Stockhouse. 2. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. 24 million, 48. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. Stockhouse. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. MONTREAL, Sept. 521. T. Further. US Headquarters. TH | February 28, 2023. View real-time stock prices and stock quotes for a full financial overview. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. T. FY2023 revenue guidance range set between $90 million and $95 million. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. By continuing to use our service, you agree to our use of cookies. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies”) with the Securities and Exchange Commission (the. 36 morning pop. . Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. By continuing to use our service, you agree to our use of cookies. Theratechnologies inc. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Nov. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. TH Stock Message Board for Investors. com uses cookies on this site. TH | September 5, 2023. Watch list NEW Set a price target alert After Hours Last. com. com uses cookies on this site. A live webcast of Dr. $44. The financial results presented in this press release are taken from the. Stockhouse. MONTREAL, Feb. communications@theratech. S. - Q3 2022 Consolidated. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. Find the latest Theratechnologies Inc. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. stock news by MarketWatch. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. Theratechnologies had a negative net margin of 36. 5%. 26 +15. com uses cookies on this site. com uses cookies on this site. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. However, only about 4% of the stocks on the OTC market fall into this category. MONTREAL, Oct. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 40 f102M H1. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. Conjugating the short peptide with various anti-cancer agents allows for. Last Reviewed: February 24, 2023. We also use them to share usage. Senior Director, Communications & Corporate Affairs. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. Vice President, Communications and Corporate Affairs. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. 65 per cent to C$1. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. $103. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. stockhouse. [email protected] Inc: Overview. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. ("Theratechnologies" or the "Company"). View real-time stock prices and stock quotes for a full financial overview. Register for your free account today at data. MONTREAL, Feb. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Christian Marsolais, Ph. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. . 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Revenues have been growing at an average rate of 10. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Investor Relations. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Sept. Theratechnologies . com. THERATECHNOLOGIES INC. 65 per cent to C$1. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Company Description: Theratechnologies is pepped up on peptides. T. 60%. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. We currently market prescription products for people with HIV in the United States. -based clinical sites participating in the conduct of the Phase. 1M. 49) by $0. By continuing to use our service, you agree to our use of cookies. Pour les émetteurs. TH | Complete Theratechnologies Inc. 69, 1. View real-time stock prices and stock quotes for a full financial overview. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Browse posts by Sector and Subsector. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. Stockhouse. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. (2013-04-03 | TSX:TH) Theratechnologies Inc. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. For investor inquiries: Leah Gibson. Stockhouse. Market Cap. It's a different kind of fat that may require a different type of treatment. By continuing to use our service, you agree to our use of cookies. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. Theratechnologies Inc. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. 02%. Stockhouse. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. Wainwright NASH Investor Conference. Further. Further. By continuing to use our service, you agree to our use of cookies. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. W. TH | September 5, 2023. 57%) Q1 2020 Earnings Call. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. e. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. $30. MONTREAL, Jan. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. ASP | Complete Acerus Pharmaceuticals Corp. By continuing to use our service, you agree to our use of cookies. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. FY2023 revenue guidance range set between $90 million and $95 million. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. com uses cookies on this site. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. Theratechnologies Announces 1-for-4 Reverse Stock Split. stock news by MarketWatch. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter.